Health & MedicineBreaking NewsBreakingLatest News
AstraZeneca’s Experimental Stomach Cancer Drug Doubles Survival in Late-Stage Trial
Sentiment: PositiveHigh Priority
What Happened?
AstraZeneca's experimental drug, sonesitatug vedotin, has shown promising results in a late-stage trial, doubling survival time for advanced stomach cancer patients. The findings were presented at the ESMO Congress in Madrid.
Key points
- Sonesitatug vedotin, or Sone-ve, increased median survival to 10 months compared to 5 months for chemotherapy.
- The trial involved 532 patients with advanced gastric cancer.
- A 53% reduction in the risk of death was observed in patients taking Sone-ve.
- The drug did not achieve statistical significance for progression-free survival.
- Sone-ve has Orphan Drug Designation from the FDA and the European Commission.
Key insights
- If approved, Sone-ve may replace traditional chemotherapy for gastric cancer treatment.
- The trial's results could lead to increased investment in antibody drug conjugates.
- The lower threshold for CLDN18.2 positivity may expand treatment eligibility for more patients.
Why it matters
The results could significantly impact treatment options for patients with advanced gastric cancer, a condition with low survival rates.
Tags
Entities
AstraZeneca· CompanySonesitatug vedotin· ProductESMO Congress· EventClaudin 18.2· Technology
Source
Times Now
